SBM:CC - Sirona Biochem Eyes Licensing Deal for Anti-aging Compound After Clinical Trial Results

2023-05-11 15:55:00 ET

Sirona Biochem (TSXV:SBM) is looking forward to securing a licensing deal after a clinical trial for its novel anti-aging compound TFC-1326 showed exceptional results, according to Géraldine Deliencourt-Godefroy, the company’s chief scientific officer.

“We have ongoing discussions with different partners that have shown interest in this compound … we have an event in Boston where we (will) share with other prospects (the) best results in order to find a way to license this compound,” Deliencourt-Godefroy said.

The clinical trial was conducted among 20 volunteers who used the compound in cream form two times a day for three months.

For further details see: